Litcius/Paper detail

Sulfur metabolism as a new therapeutic target of heart failure

Akiyuki Nishimura, Xiaokang Tang, Liuchenzi Zhou, T. Ito, Yuri Kato, Motohiro Nishida

2024Journal of Pharmacological Sciences11 citationsDOIOpen Access PDF

Abstract

Sulfur-based redox signaling has long attracted attention as critical mechanisms underlying the development of cardiac diseases and resultant heart failure. Especially, post-translational modifications of cysteine (Cys) thiols in proteins mediate oxidative stress-dependent cardiac remodeling including myocardial hypertrophy, senescence, and interstitial fibrosis. However, we recently revealed the existence of Cys persulfides and Cys polysulfides in cells and tissues, which show higher redox activities than Cys and substantially contribute to redox signaling and energy metabolism. We have established simple evaluation methods that can detect polysulfides in proteins and inorganic polysulfides in cells and revealed that polysulfides abundantly expressed in normal hearts are dramatically catabolized by exposure to ischemic/hypoxic and environmental electrophilic stress, which causes vulnerability of the heart to mechanical load. Accumulation of hydrogen sulfide, a nucleophilic catabolite of persulfides/polysulfides, may lead to reductive stress in ischemic hearts, and perturbation of polysulfide catabolism can improve chronic heart failure after myocardial infarction in mice. This review focuses on the (patho)physiological role of sulfur metabolism in hearts, and proposes that sulfur catabolism during ischemic/hypoxic stress has great potential as a new therapeutic strategy for the treatment of ischemic heart failure.

Topics & Concepts

PolysulfideOxidative stressSulfur metabolismChemistrySulfurHeart failureCatabolismRedoxMetabolismBiochemistryInternal medicineCell biologyMedicineBiologyInorganic chemistryElectrolytePhysical chemistryElectrodeOrganic chemistrySulfur Compounds in BiologyRedox biology and oxidative stressElectron Spin Resonance Studies
Sulfur metabolism as a new therapeutic target of heart failure | Litcius